Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Genocea Biosciences Inc (NASDAQ:GNCA)

12.21
Delayed Data
As of Aug 28
 -0.06 / -0.49%
Today’s Change
6.15
Today|||52-Week Range
16.18
+74.43%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$342.6M

Company Description

Genocea Biosciences, Inc. operates as a clinical stage biotechnology company, which discovers and develops novel vaccines to address infectious diseases. The company uses its proprietary platform technology, antigen lead acquisition system to discover and develop novel vaccine candidates. Its products include GEN-001, GEN-002, GEN-003, GEN-004 and GEN-005. Genocea Biosciences was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

Contact Information

Genocea Biosciences, Inc.
Cambridge Discovery Park
Cambridge Massachusetts 02140
P:(617) 876-8191
Investor Relations:
(617) 715-7795

Employees

Shareholders

Individual stakeholders30.95%
Mutual fund holders20.90%
Other institutional20.34%

Top Executives

William D. ClarkPresident, Chief Executive Officer & Director
Jonathan Michael PooleChief Financial & Accounting Officer
Jessica Baker FlechtnerSenior Vice President-Research
Seth V. HetheringtonChief Medical Officer
Robert E. FarrellVice President-Finance & Administration